{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T01:00:28Z","timestamp":1781053228494,"version":"3.54.1"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.leukres.2026.108252","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T20:08:09Z","timestamp":1779221289000},"page":"108252","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Economic burden of leukemia diagnosis and treatment in South Africa: A retrospective cost of illness analysis"],"prefix":"10.1016","volume":"166","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1840-1176","authenticated-orcid":false,"given":"Rochelle","family":"Woudberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5202-7702","authenticated-orcid":false,"given":"Sarah Muriel","family":"Meiring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edina","family":"Sinanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.leukres.2026.108252_bib1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.leukres.2026.108252_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2020.598215","article-title":"The Current Situation and Future Trend of Leukemia Mortality by Sex and Area in China","volume":"8","author":"Li","year":"2020","journal-title":"Front Public Health"},{"key":"10.1016\/j.leukres.2026.108252_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.33588","article-title":"Cancer statistics for the year 2020: An overview","author":"Ferlay","year":"2021","journal-title":"Int J. Cancer"},{"issue":"6","key":"10.1016\/j.leukres.2026.108252_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0325937","article-title":"Global, regional, and national burden of leukemia: Epidemiological trends analysis from 1990 to 2021","volume":"20","author":"Hu","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.leukres.2026.108252_bib5","article-title":"Disease Burden, Risk Factors, and Trends of Leukaemia: A Global Analysis","volume":"12","author":"Huang","year":"2022","journal-title":"Front Oncol."},{"key":"10.1016\/j.leukres.2026.108252_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2025.102818","article-title":"Leukemia epidemiology and burden of disease in South Africa: 2015\u20132019","volume":"97","author":"Woudberg","year":"2025","journal-title":"Cancer Epidemiol."},{"key":"10.1016\/j.leukres.2026.108252_bib7","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1146\/annurev-pathol-042320-034052","article-title":"Precision Medicine in Low- and Middle-Income Countries","volume":"17","author":"Radich","year":"2022","journal-title":"Annu Rev. Pathol."},{"key":"10.1016\/j.leukres.2026.108252_bib8","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/1471-2407-14-224","article-title":"The cost of lost productivity due to premature cancer-related mortality: an economic measure of the cancer burden","volume":"14","author":"Hanly","year":"2014","journal-title":"BMC Cancer"},{"issue":"S1","key":"10.1016\/j.leukres.2026.108252_bib9","doi-asserted-by":"crossref","DOI":"10.1186\/s12913-021-06171-3","article-title":"Is South Africa closing the health gaps between districts? Monitoring progress towards universal health service coverage with routine facility data","volume":"21","author":"Day","year":"2021","journal-title":"BMC Health Serv. Res."},{"issue":"1","key":"10.1016\/j.leukres.2026.108252_bib10","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12939-023-01962-y","article-title":"Addressing cancer care inequities in sub-Saharan Africa: current challenges and proposed solutions","volume":"22","author":"Omotoso","year":"2023","journal-title":"Int J. Equity Health"},{"key":"10.1016\/j.leukres.2026.108252_bib11","first-page":"1","article-title":"Chronic lymphocytic leukaemia trends and features at a tertiary hospital in South Africa (2011\u20132016)","volume":"5","author":"Musaigwa","year":"2021","journal-title":"South Afr. J. Oncol."},{"issue":"12","key":"10.1016\/j.leukres.2026.108252_bib12","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s40273-022-01189-9","article-title":"A Systematic Literature Review of the Economic Evaluations of Treatments for Patients with Chronic Myeloid Leukemia","volume":"40","author":"Agrawal","year":"2022","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.leukres.2026.108252_bib13","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1750-1172-8-32","article-title":"Cost of illness and economic burden of chronic lymphocytic leukemia","volume":"8","author":"Blankart","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"issue":"9","key":"10.1016\/j.leukres.2026.108252_bib14","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1080\/13696998.2017.1345750","article-title":"Evaluation of healthcare resource utilization and incremental economic burden of patients with chronic myeloid leukemia after disease progression to blast phase","volume":"20","author":"Jabbour","year":"2017","journal-title":"J. Med Econ."},{"issue":"12","key":"10.1016\/j.leukres.2026.108252_bib15","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1080\/03007995.2022.2133468","article-title":"Clinical and economic burden of first-line chemoimmunotherapy by risk status in chronic lymphocytic leukemia","volume":"38","author":"Leslie","year":"2022","journal-title":"Curr. Med Res Opin."},{"issue":"16","key":"10.1016\/j.leukres.2026.108252_bib16","first-page":"S347","article-title":"Unmet clinical needs and economic burden of disease in the treatment landscape of acute myeloid leukemia","volume":"24","author":"Wiese","year":"2018","journal-title":"Am. J. Manag Care"},{"issue":"1","key":"10.1016\/j.leukres.2026.108252_bib17","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1586\/17474086.2016.1112735","article-title":"Economic burden associated with acute myeloid leukemia treatment","volume":"9","author":"Zeidan","year":"2016","journal-title":"Expert Rev. Hematol."},{"issue":"3","key":"10.1016\/j.leukres.2026.108252_bib18","doi-asserted-by":"crossref","first-page":"A147","DOI":"10.1016\/j.jval.2016.03.1574","article-title":"Direct Medical Costs of Treating Chronic Lymphocytic Leukemia Patients in the Private Healthcare System in Brazil: Results From A 24-Month Retrospective Analysis of an Administrative Database","volume":"19","author":"Paloni","year":"2016","journal-title":"Value Health"},{"issue":"9","key":"10.1016\/j.leukres.2026.108252_bib19","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.jcma.2018.02.005","article-title":"Cost of illness of leukemia in Japan - Trend analysis and future projections","volume":"81","author":"Amin","year":"2018","journal-title":"J. Chin. Med Assoc."},{"key":"10.1016\/j.leukres.2026.108252_bib20","doi-asserted-by":"crossref","DOI":"10.3402\/gha.v7.23573","article-title":"Step-by-step guideline for disease-specific costing studies in low- and middle-income countries: a mixed methodology","volume":"7","author":"Hendriks","year":"2014","journal-title":"Glob. Health Action"},{"key":"10.1016\/j.leukres.2026.108252_bib21","series-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"2015"},{"key":"10.1016\/j.leukres.2026.108252_bib22","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12913-016-1364-z","article-title":"Modelling the healthcare costs of skin cancer in South Africa","volume":"16","author":"Gordon","year":"2016","journal-title":"BMC Health Serv. Res"},{"issue":"1","key":"10.1016\/j.leukres.2026.108252_bib23","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13561-021-00322-2","article-title":"Economic burden of lung cancer in Turkey: a cost of illness study from payer perspective","volume":"11","author":"Cicin","year":"2021","journal-title":"Health Econ. Rev."},{"issue":"8","key":"10.1016\/j.leukres.2026.108252_bib24","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2165\/11588380-000000000-00000","article-title":"Cost-of-illness studies: a guide to critical evaluation","volume":"29","author":"Larg","year":"2011","journal-title":"Pharmacoeconomics"},{"issue":"8","key":"10.1016\/j.leukres.2026.108252_bib25","doi-asserted-by":"crossref","first-page":"e414","DOI":"10.1016\/S1470-2045(15)00162-X","article-title":"Establishment of a cancer surveillance programme: the South African experience","volume":"16","author":"Singh","year":"2015","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.leukres.2026.108252_bib26","doi-asserted-by":"crossref","first-page":"107","DOI":"10.7196\/SAMJ.8858","article-title":"South African National Cancer Registry: Effect of withheld data from private health systems on cancer incidence estimates","volume":"105","author":"Singh","year":"2015","journal-title":"S Afr. Med J."},{"issue":"9","key":"10.1016\/j.leukres.2026.108252_bib27","doi-asserted-by":"crossref","first-page":"e642","DOI":"10.1016\/S2214-109X(16)30113-9","article-title":"Mortality trends and differentials in South Africa from 1997 to 2012: second National Burden of Disease Study","volume":"4","author":"Pillay-van Wyk","year":"2016","journal-title":"Lancet Glob. Health"},{"issue":"5","key":"10.1016\/j.leukres.2026.108252_bib28","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J. Cancer"},{"issue":"8","key":"10.1016\/j.leukres.2026.108252_bib29","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s10552-025-01979-4","article-title":"Priority setting for improved leukemia management and research in South Africa: a modified Delphi study","volume":"36","author":"Woudberg","year":"2025","journal-title":"Cancer Causes & Control"},{"issue":"1","key":"10.1016\/j.leukres.2026.108252_bib30","doi-asserted-by":"crossref","first-page":"43","DOI":"10.6004\/jnccn.2024.0007","article-title":"Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","author":"Shah","year":"2024","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"6","key":"10.1016\/j.leukres.2026.108252_bib31","doi-asserted-by":"crossref","first-page":"622","DOI":"10.6004\/jnccn.2022.0031","article-title":"NCCN Guidelines\u00ae Insights: Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma, Version 3.2022","volume":"20","author":"Wierda","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"8","key":"10.1016\/j.leukres.2026.108252_bib32","doi-asserted-by":"crossref","first-page":"563","DOI":"10.6004\/jnccn.2024.0051","article-title":"Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","author":"Shah","year":"2024","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"1","key":"10.1016\/j.leukres.2026.108252_bib33","doi-asserted-by":"crossref","first-page":"16","DOI":"10.6004\/jnccn.2021.0002","article-title":"NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021","volume":"19","author":"Pollyea","year":"2021","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"1","key":"10.1016\/j.leukres.2026.108252_bib34","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.leukres.2026.108252_bib35","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.annonc.2020.02.018","article-title":"Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020","volume":"31","author":"Heuser","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.leukres.2026.108252_bib36","first-page":"279.e1","article-title":"An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia","volume":"29","author":"Tokaz","year":"2023"},{"issue":"9","key":"10.1016\/j.leukres.2026.108252_bib37","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1016\/j.clml.2024.05.009","volume":"24","author":"Ghosh","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"3","key":"10.1016\/j.leukres.2026.108252_bib38","doi-asserted-by":"crossref","first-page":"e360","DOI":"10.1093\/oncolo\/oyad324","article-title":"Treatment Patterns, Healthcare Resource Utilization, and Costs of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in the US","volume":"29","author":"Yang","year":"2024","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.leukres.2026.108252_bib39","first-page":"840","article-title":"Recommendations for the management of adult chronic myeloid leukaemia in South Africa","volume":"101","author":"Louw","year":"2011","journal-title":"S Afr. Med J."},{"key":"10.1016\/j.leukres.2026.108252_bib40","article-title":"Chronic myeloid leukaemia in the South African public health setting: Are we reaching the European LeukemiaNet targets for frontline therapy?","volume":"4","author":"Sikhipha","year":"2020","journal-title":"South Afr. J. Oncol."},{"key":"10.1016\/j.leukres.2026.108252_bib41","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1182\/blood-2021-147912","article-title":"Acute Lymphoblastic Leukaemia in Johannesburg, South Africa: The State-Sector Experience","volume":"138","author":"Vaughan","year":"2021","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.leukres.2026.108252_bib42","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.leukres.2026.108252_bib43","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/bmt.2016.282","article-title":"Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation","volume":"52","author":"van Gelder","year":"2017","journal-title":"Bone Marrow Transplant."},{"issue":"17","key":"10.1016\/j.leukres.2026.108252_bib44","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1182\/bloodadvances.2020002184","article-title":"Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia","volume":"4","author":"Kim","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2026.108252_bib45","unstructured":"NHLS, NHLS State Price List 2018. 2018."},{"key":"10.1016\/j.leukres.2026.108252_bib46","unstructured":"Africa, N.S., National Department of Health South Africa. Uniform Patient Fee Schedule Tarriffs 2024: Tshwane."},{"key":"10.1016\/j.leukres.2026.108252_bib47","unstructured":"Health, S.A.N.Do, Database of Medicine Prices 30 August 2024. 2024."},{"issue":"3","key":"10.1016\/j.leukres.2026.108252_bib48","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2307\/3349801","article-title":"Cost-of-illness methodology: a guide to current practices and procedures","volume":"60","author":"Hodgson","year":"1982","journal-title":"Milbank Mem. Fund. Q Health Soc."},{"key":"10.1016\/j.leukres.2026.108252_bib49","unstructured":"StatsSA, Statistics South Africa. Monthly earning in South Africa, 2017-2022. 2024."},{"issue":"1","key":"10.1016\/j.leukres.2026.108252_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S0266462322000265","article-title":"Health Technology Assessment in Support of National Health Insurance in South Africa","volume":"38","author":"Wilkinson","year":"2022","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"10.1016\/j.leukres.2026.108252_bib51","unstructured":"StatsSA, Statistics South Africa. South Africa. Mid-year population estimates 2022. 2022."},{"key":"10.1016\/j.leukres.2026.108252_bib52","series-title":"South African medicine price registry","author":"NDoH","year":"2019"},{"issue":"4","key":"10.1016\/j.leukres.2026.108252_bib53","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/cam4.597","article-title":"Hematologic malignancies in South Africa 2000-2006: analysis of data reported to the National Cancer Registry","volume":"5","author":"Schonfeld","year":"2016","journal-title":"Cancer Med"},{"key":"10.1016\/j.leukres.2026.108252_bib54","article-title":"Estimating the burden of cancer in South Africa","volume":"6","author":"Finestone","year":"2022","journal-title":"South Afr. J. Oncol."},{"key":"10.1016\/j.leukres.2026.108252_bib55","doi-asserted-by":"crossref","DOI":"10.7196\/SAMJ.2026.v116i1.2678","article-title":"Costing the national clinical guidelines for prostate cancer control and management in South Africa: Public sector perspective","author":"Thsehla","year":"2026","journal-title":"South Afr. Med. J."},{"issue":"10","key":"10.1016\/j.leukres.2026.108252_bib56","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-036341","article-title":"Economic burden of cancers in Taiwan: a direct and indirect cost estimate for 2007-2017","volume":"10","author":"Huang","year":"2020","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.leukres.2026.108252_bib57","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s12325-022-02398-6","article-title":"The Economic Burden of Chronic Myeloid Leukemia in Patients with Later Lines: Findings from a Real-World Analysis in Italy","volume":"40","author":"Breccia","year":"2023","journal-title":"Adv. Ther."},{"issue":"32","key":"10.1016\/j.leukres.2026.108252_bib58","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.2217\/fon-2022-0706","article-title":"Economic burden in US patients with newly diagnosed acute myeloid leukemia receiving intensive induction chemotherapy","volume":"18","author":"Huggar","year":"2022","journal-title":"Future Oncol."},{"key":"10.1016\/j.leukres.2026.108252_bib59","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2147\/JBM.S279736","article-title":"What Does the Economic Burden of Acute Myeloid Leukemia Treatment Look Like for the Next Decade? An Analysis of Key Findings, Challenges and Recommendations","volume":"12","author":"Forsythe","year":"2021","journal-title":"J. Blood Med"},{"issue":"3","key":"10.1016\/j.leukres.2026.108252_bib60","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.7314\/APJCP.2015.16.3.1295","article-title":"The economic burden of cancer in Korea in 2009","volume":"16","author":"Kim","year":"2015","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"11","key":"10.1016\/j.leukres.2026.108252_bib61","first-page":"2599","article-title":"The Economic Burden of Acute Myeloid Leukemia in Iran","volume":"51","author":"Alipour","year":"2022","journal-title":"Iran. J. Public Health"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626000962?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626000962?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:39:06Z","timestamp":1781051946000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212626000962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":61,"alternative-id":["S0145212626000962"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108252","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Economic burden of leukemia diagnosis and treatment in South Africa: A retrospective cost of illness analysis","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108252","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108252"}}